ICON Public Limited (NASDAQ:ICLR) Position Trimmed by TD Private Client Wealth LLC

TD Private Client Wealth LLC reduced its holdings in ICON Public Limited (NASDAQ:ICLR) by 83.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 568 shares of the medical research company’s stock after selling 2,842 shares during the quarter. TD Private Client Wealth LLC’s holdings in ICON Public were worth $119,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Sierra Ocean LLC acquired a new stake in ICON Public during the fourth quarter worth about $29,000. Park Place Capital Corp grew its holdings in shares of ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 166 shares during the last quarter. Private Trust Co. NA lifted its holdings in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after purchasing an additional 82 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the last quarter. Finally, Horizon Investments LLC grew its stake in ICON Public by 534.0% during the 4th quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock worth $137,000 after buying an additional 550 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Citigroup cut their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. JPMorgan Chase & Co. reduced their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Robert W. Baird dropped their price target on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Barclays reduced their price objective on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research report on Friday, February 21st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a research report on Wednesday, January 15th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ICON Public has a consensus rating of “Moderate Buy” and a consensus price target of $272.50.

ICON Public Trading Down 2.9 %

Shares of ICON Public stock opened at $179.02 on Wednesday. The business has a fifty day simple moving average of $191.67 and a 200-day simple moving average of $223.96. ICON Public Limited has a fifty-two week low of $174.93 and a fifty-two week high of $347.72. The firm has a market cap of $14.46 billion, a price-to-earnings ratio of 18.78, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. On average, equities analysts forecast that ICON Public Limited will post 13.38 EPS for the current fiscal year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.